ECSP066807A - Formulaciones galénicas de compuestos orgánicos - Google Patents

Formulaciones galénicas de compuestos orgánicos

Info

Publication number
ECSP066807A
ECSP066807A EC2006006807A ECSP066807A ECSP066807A EC SP066807 A ECSP066807 A EC SP066807A EC 2006006807 A EC2006006807 A EC 2006006807A EC SP066807 A ECSP066807 A EC SP066807A EC SP066807 A ECSP066807 A EC SP066807A
Authority
EC
Ecuador
Prior art keywords
organic compounds
galenic formulations
present
weight
amount
Prior art date
Application number
EC2006006807A
Other languages
English (en)
Inventor
Petra Gisela Rigassi-Dietrich
Martin Schmid
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34994415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066807(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP066807A publication Critical patent/ECSP066807A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una forma de dosis oral sólida que comprende una cantidad terapéuticamente efectiva de alisciren o una sal farmacéuticamente aceptable del mismo, y en donde el ingrediente activo está presente en una cantidad de más de 46% en peso, basado en el peso total de la forma de dosis oral.
EC2006006807A 2004-03-17 2006-08-30 Formulaciones galénicas de compuestos orgánicos ECSP066807A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55387804P 2004-03-17 2004-03-17

Publications (1)

Publication Number Publication Date
ECSP066807A true ECSP066807A (es) 2006-11-16

Family

ID=34994415

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006807A ECSP066807A (es) 2004-03-17 2006-08-30 Formulaciones galénicas de compuestos orgánicos

Country Status (24)

Country Link
US (3) US8617595B2 (es)
EP (2) EP2283826B1 (es)
JP (2) JP2007529456A (es)
KR (2) KR101353736B1 (es)
CN (2) CN103462913A (es)
AR (1) AR048431A1 (es)
AU (2) AU2005224010B2 (es)
BR (1) BRPI0508833A (es)
CA (1) CA2554633C (es)
EC (1) ECSP066807A (es)
ES (1) ES2747941T3 (es)
IL (1) IL177424A0 (es)
MA (1) MA28490B1 (es)
MX (1) MX347617B (es)
MY (2) MY144477A (es)
NO (1) NO343217B1 (es)
NZ (1) NZ548823A (es)
PE (3) PE20110121A1 (es)
RU (3) RU2384328C2 (es)
SG (1) SG153830A1 (es)
TN (1) TNSN06294A1 (es)
TW (1) TWI406656B (es)
WO (1) WO2005089729A2 (es)
ZA (1) ZA200606220B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003303956A1 (en) * 2002-11-05 2004-11-23 Smithkline Beecham Corporation Antibacterial agents
US20070191487A1 (en) * 2004-03-17 2007-08-16 Rigassi-Dietrich Petra G Galenic formulations of organic compounds
TW200804241A (en) * 2006-02-24 2008-01-16 Novartis Ag New salt
GB0605688D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic compounds
SG170830A1 (en) * 2006-04-03 2011-05-30 Novartis Ag Renin inhibitors for the treatment of hypertension
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
EP1891937A1 (en) * 2006-08-25 2008-02-27 Novartis AG Galenic formulations of aliskiren
CA2563690C (en) * 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
US8119841B2 (en) * 2006-11-07 2012-02-21 Novartis Ag Crystalline forms of aliskiren hemifumarate
EP2089356B1 (en) * 2006-11-09 2012-04-25 Novartis AG Salt of aliskiren with orotic acid
JP2010518147A (ja) * 2007-02-16 2010-05-27 ノバルティス アーゲー 有機化合物の使用
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
US20090082458A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched aliskiren
KR20100076996A (ko) * 2007-09-28 2010-07-06 노파르티스 아게 알리스키렌의 생약 제형
EP2205279B1 (en) * 2007-09-28 2011-04-13 Novartis AG Pharmaceutical combination of aliskiren and valsartan
AR066168A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Formulaciones galenicas de compuestos organicos
BRPI0822652A2 (pt) 2007-11-13 2015-06-23 Teva Pharmáceutica Ind Ltd Petach Tirva 49131 Fórmulas polimórficas de hemifumarato de alisquireno e processos para a sua preparação
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
WO2009149344A2 (en) * 2008-06-06 2009-12-10 Teva Pharmaceutical Industries Ltd. Solid states of aliskiren free base
EP2143425A1 (de) 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
JP2010031006A (ja) * 2008-07-17 2010-02-12 Novartis Ag 有機化合物の使用
JO3239B1 (ar) * 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
US9026212B2 (en) 2008-09-23 2015-05-05 Incube Labs, Llc Energy harvesting mechanism for medical devices
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
SI2189442T1 (sl) 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
TWI468191B (zh) 2009-01-28 2015-01-11 Novartis Ag 有機化合物之調配物
EP2340820A1 (en) 2009-12-16 2011-07-06 KRKA, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
EP2393489B1 (en) 2009-02-05 2014-10-08 Krka, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
EP2216020A1 (en) 2009-02-05 2010-08-11 KRKA, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
CN102348452A (zh) 2009-03-20 2012-02-08 诺瓦提斯公司 缬沙坦和阿利吉仑的固定剂量组合的盖仑制剂
US20120003308A1 (en) 2009-03-20 2012-01-05 Sonali Bose Pharmaceutical Composition Comprising Aliskiren
JP2010280601A (ja) * 2009-06-04 2010-12-16 Suntory Holdings Ltd キシロオリゴ糖高含有錠剤
WO2011028919A2 (en) 2009-09-03 2011-03-10 Teva Pharmaceutical Industries Ltd. Solid forms of aliskiren hemifumarate and processes for preparation thereof
EP2382967A1 (de) 2010-04-21 2011-11-02 ratiopharm GmbH Aliskiren in Form einer festen Dispersion
EP2382969A1 (en) 2010-04-30 2011-11-02 Sanovel Ilac Sanayi ve Ticaret A.S. Multicoated Aliskiren formulations
US20130129791A1 (en) * 2010-05-04 2013-05-23 Mahmut Bilgic Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof
US10835495B2 (en) 2012-11-14 2020-11-17 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
CN103099793B (zh) * 2013-02-06 2015-07-15 中国人民解放军第二军医大学 片剂及其制备方法
CN103536576B (zh) * 2013-10-15 2015-07-01 海南卫康制药(潜山)有限公司 阿利吉仑组合物胶囊
RU2545833C1 (ru) * 2013-12-03 2015-04-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПХФА Минздрава России) Фармацевтическая композиция с антиишемической и антиоксидантной активностью и способ ее получения
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
EP4085902B1 (en) * 2019-12-31 2025-04-30 Jiangsu Yahong Meditech Co., Ltd. Pharmaceutical composition containing nitroxoline, nitroxoline tablet, preparation method therefor and use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3039922A (en) * 1959-08-17 1962-06-19 Carter Prod Inc Method of administering tablets having decongestant and anti-histaminic activity
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
DE19820801A1 (de) * 1998-05-09 1999-11-25 Gruenenthal Gmbh Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
ES2310164T3 (es) * 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
US6264983B1 (en) * 1999-09-16 2001-07-24 Rhodia, Inc. Directly compressible, ultra fine acetaminophen compositions and process for producing same
US20030187038A1 (en) 2000-08-25 2003-10-02 Yoshimi Imura Fibrinogen-lowering agents
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US7316819B2 (en) * 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
EP1250921A1 (en) * 2001-04-21 2002-10-23 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Fast disintegrating meloxicam tablet
JP2003015880A (ja) * 2001-06-29 2003-01-17 Toshiba Corp 携帯情報端末およびアドインプログラム起動方法
CN1571668A (zh) 2001-10-18 2005-01-26 诺瓦提斯公司 At1－受体拮抗剂和心血管药物形成的盐
US20030114389A1 (en) * 2001-11-13 2003-06-19 Webb Randy Lee Combination of organic compounds
KR20100137026A (ko) * 2002-05-17 2010-12-29 노파르티스 아게 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물
WO2004002466A1 (en) * 2002-06-28 2004-01-08 Speedel Pharma Ag Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant
US20040002520A1 (en) * 2002-07-01 2004-01-01 Soderlund Patrick L. Composition and method for cessation of Nicotine cravings

Also Published As

Publication number Publication date
AR048431A1 (es) 2006-04-26
RU2006136090A (ru) 2008-04-27
MY144477A (en) 2011-09-30
US8007824B2 (en) 2011-08-30
CN1997354A (zh) 2007-07-11
PE20060075A1 (es) 2006-03-20
PE20110121A1 (es) 2011-02-28
US20050272790A1 (en) 2005-12-08
US20060018960A1 (en) 2006-01-26
EP2283826A2 (en) 2011-02-16
ES2747941T3 (es) 2020-03-12
EP2283826A3 (en) 2013-08-07
CN1997354B (zh) 2013-09-11
EP1729736A2 (en) 2006-12-13
RU2011135405A (ru) 2013-03-10
TW200534843A (en) 2005-11-01
KR20130028803A (ko) 2013-03-19
PE20142101A1 (es) 2014-12-27
WO2005089729A2 (en) 2005-09-29
RU2384328C2 (ru) 2010-03-20
TWI406656B (zh) 2013-09-01
AU2005224010B2 (en) 2009-02-26
RU2438661C2 (ru) 2012-01-10
NO343217B1 (no) 2018-12-03
US20070197655A1 (en) 2007-08-23
EP2283826B1 (en) 2019-09-04
JP2012211152A (ja) 2012-11-01
ZA200606220B (en) 2008-04-30
BRPI0508833A (pt) 2007-08-14
CA2554633A1 (en) 2006-09-29
NO20064670L (no) 2006-10-16
MX347617B (es) 2017-05-04
IL177424A0 (en) 2008-03-20
KR20070006776A (ko) 2007-01-11
CA2554633C (en) 2014-07-08
WO2005089729A3 (en) 2006-10-12
MY148773A (en) 2013-05-31
KR101274855B1 (ko) 2013-06-13
SG153830A1 (en) 2009-07-29
CN103462913A (zh) 2013-12-25
RU2009138446A (ru) 2011-04-27
JP2007529456A (ja) 2007-10-25
AU2005224010A1 (en) 2005-09-29
MA28490B1 (fr) 2007-03-01
KR101353736B1 (ko) 2014-01-22
AU2009202069A1 (en) 2009-06-18
NZ548823A (en) 2011-02-25
TNSN06294A1 (en) 2007-12-03
US8617595B2 (en) 2013-12-31
US7683054B2 (en) 2010-03-23
RU2480210C1 (ru) 2013-04-27
AU2009202069B2 (en) 2012-02-16
JP5925607B2 (ja) 2016-05-25

Similar Documents

Publication Publication Date Title
AR048431A1 (es) Formulaciones galenicas de compuestos organicos
ECSP055733A (es) Tabletas dispersables de deferacirox
AR054064A1 (es) Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas
NL300889I2 (nl) Trifluridine in combinatie met tipiracilhydrochloride
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
CO6241104A2 (es) "composiciones farmaceuticas que comprende {4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil}-5-cloro-tiofen-2-il-sulfonilurea o sales de la misma para la inhibicion de la agregacion de plaquetas inducidas por adp"
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
AR039335A1 (es) Tableta de carga de droga alta
NO20062004L (no) Forlenget frigjoring farmasoytiske blandinger omfattene aplindor og derivater derav
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
WO2008023016A3 (en) Galenic formulations of aliskiren
CO6160321A2 (es) Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo
CO5390076A1 (es) Composiciones farmaceuticas
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
CY1114163T1 (el) Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση
PA8629501A1 (es) Tabletas dispersables que comprenden un derivado de acido benzoico
AR061233A1 (es) Formulacion de liberacion prolongada de naltrexona
CO5640087A2 (es) Composiciones de farmacos anti-inflamatorios no esteroideos descongestionantes y anti-histaminicos
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
JP2011500589A5 (es)
WO2008065144A3 (en) Galenic formulations of organic compounds
MA32722B1 (fr) Formulation galénique renfermant de l'aliskirène et procédé associé de préparation par granulation par fusion-extrusion
CO6270216A2 (es) Formulaciones galenicas de alisquireno